Pharmaceutical Research Associates Group B.V.
Verified site
Groningen, The Netherlands
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
The investigation focuses on a medication called BAY 2927088 that is being developed for the treatment of advanced non‑small cell lung cancer that carries the genetic changes known as EGFR and HER2. The main goal of the trial is to learn how much of the drug reaches the bloodstream when taken by mouth compared with a very small dose given through an intravenous infusion, and to see how the body processes and eliminates the drug.
Healthy adult men will receive a single oral tablet of the drug and, on a separate day, a tiny trace‑labeled dose given by the infusion. Blood and urine samples will be collected over several days to measure the drug and the harmless radioactivity that marks it. The study also tracks how the drug is excreted in urine and stool to understand its overall clearance. Safety checks will be performed throughout, and any side effects will be recorded.
The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.
10 criteria
10 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Groningen, The Netherlands
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
This is the same investigational drug given through a needle into a vein. It is supplied as a concentrate that is mixed with fluid and infused slowly. In the study a very small, radio‑labeled amount is injected so researchers can track exactly how the drug moves through the body and is eliminated.
This form of the drug is a liquid that is swallowed. It is used in the second part of the trial to see how the medication is absorbed when taken as a solution and to measure how much of the drug and its radioactive label are excreted in urine and feces.
This is a solid pill with a protective coating that is taken by mouth. The tablet is used in the first part of the trial to compare how well the drug is absorbed from a typical oral dose with the absorption seen after the intravenous microdose.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.